Kornimate/medical-research-clean huggingface dataset:
nebulized heparin for covid19-associated acute respiratory failure

Conditions: Covid19

Summary: the objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in covid-19 and prevent harmful effects possible with systemic anticoagulation.


Eligibility criteria:
inclusion criteria: patients admitted with confirmed covid-19 receiving mechanical ventilation for ards (pao2/fio2 ratio =300) within 48 hours exclusion criteria: * allergy to heparin * any history of heparin-induced thrombocytopenia * high risk of bleeding (platelet count \ 1.5) * patients with known bleeding disorders (i.e. hemophilia or von willebrand disease) * active bleeding * pulmonary bleeding during this hospital admission (pulmonary bleeding is frank bleeding in the lungs, trachea or bronchi with repeated hemoptysis, or requiring repeated suctioning, and temporally associated with acute deterioration in respiratory status) * neurosurgical procedures during this hospital admission or such procedures are planned * epidural catheter in place * any history of intracranial, spinal or epidural hemorrhage * tracheostomy in place * cervical spinal cord injury associated with reduced long-term ability to breathe independently * spinal or peripheral nerve disease with a likely prolonged reduction in the ability to breathe independently * receiving extra-corporeal membrane oxygenation or continuous renal replacement therapy * usually treated with hemodialysis or peritoneal dialysis for end-stage renal failure * death is deemed imminent or inevitable or there is an underlying disease with a life expectancy of fewer than 90 days * pregnant or might be pregnant. * objection from the treating clinician * consent refused by the patient or substitute decision maker. * history of thrombosis (vte or cardiovascular event)
study of novel regimens in relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a multicenter, open-label, phase i/ii clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of eos884448 (also known as eos-448 or gsk4428859a), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (rrmm).


Eligibility criteria:
inclusion criteria: * all participants must have a documented diagnosis of relapse/refractory multiple myeloma and have measurable disease as defined per imwg criteria. * all participants must have received at least 3 prior lines of mm therapy with imid, pi and anti-cd-38, and progressed on their last therapy (prior bcma targeted therapy allowed). * all participants must have eastern cooperative oncology group (ecog) performance status of 0,1or 2. * all participants must have adequate organ function. * females of childbearing potential (fcbp) or male participant must agree to follow contraception requirements. exclusion criteria: * all participants with non-secretory mm * all participants with known auto-immune disease * all participants with history of life-threatening toxicity related to prior immune therapy. * all participants with active graft versus host disease after allogeneic stem cell transplantation. * all participants with active, unstable cardiovascular function. * all participants with active infection requiring systemic therapy. * all participants with hypersensitivity to any of the treatments. * all participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.

Keywords: multiple myeloma eos884448 gsk4428859a tigit anti-tigit iberdomide celmod cc-220 eos-448 belrestotug
inferior vena cava collapsibility and distensibility assessment in critical care.

Conditions: Sepsis; Acute Renal Failure; Acute Gastroenteritis; Diabetic Ketoacidosis

Summary: this study will help in determining the impact of assessment of inferior vena cava collapsibility and distensibility index (ivc ci and di) through point of care ultra sound (pocus), for the fluid management of critically ill patients. this would help in better management of such patients in resource limited countries, where costly equipment for cardiac output monitoring and fluid management are frequently not available. moreover this study will help in development of future guidelines for fluid resuscitation in critically ill patients.

the current study is a randomized clinical trial with the aim to explore comparative outcome between ivc ci and di versus clinical parameters guided fluid management groups in patients of sepsis, acute renal failure, acute gastroenteritis and diabetic ketoacidosis in terms of, 1. within 24 hours 7 day and 28 day mortality 2. change in sequential organ failure assessment (δsofa) score from baseline to 24 hours after fluid management. 3. cumulative fluid balance at 6 hours of fluid management 4. days on mechanical ventilation 5. days in intensive care unit (icu) 6. change in lactic acid levels in sepsis sub group 7. change in blood sugar random (bsr) in diabetic ketoacidosis (dka) sub group 8. change in power of hydrogen (ph) in septic and diabetic ketoacidosis sub group of participant

Eligibility criteria:
inclusion criteria: * patients admitted in critical care with systolic blood pressure \< 90 mmhg with any of the diagnosis as per operational definition: * sepsis * diabetic ketoacidosis * acute kidney injury * acute gastroenteritis exclusion criteria: * known case of right heart disease * known case of congestive cardiac failure * presence of marked ascites * ivc could not be identified or diameter could not be measured * pregnant females * body mass index (bmi) \>30 kg/meter2

Keywords: inferior vena cava collapsibility and distensibility index fluid management resuscitation clinical parameters sepsis acute gastroenteritis acute renal failure diabetic ketoacidosis mortality cumulative fluid balance lactic acid sequential organ failure assessment score mechanical ventilation critical care
comparison of the effects of cervical vasopressin versus no premedication on blood loss during vaginal hysterectomy: a randomized, placebo controlled trial

Conditions: Blood Loss During Vaginal Hysterectomy

Summary: vasoconstrictive agents are increasingly being used in order to decrease blood loss during vaginal hysterectomy. the first reported study of the use of a vasoconstrictive agent for this purpose was on the use of epinephrine injected intracervically preoperatively by england, et. al. they demonstrated a significant decrease in the amount of blood lost during the surgery but also demonstrated a significant increase in the risk of post-operative infections, most frequently a vaginal cuff cellulitis requiring antibiotic treatment. recent studies using vasopressin as the vasoconstrictive agent have also found the same significant decrease in blood loss while not demonstrating a difference in the rate of post-operative infections. the more recent studies by speer and unger , and kammerer-doak, et.al. were larger, better designed studies and are considered more credible. more surgeons are therefore injecting vasopressin intracervically preoperatively. some surgeons believe that the injection of vasopressin intracervically prior to the initial incision of a vaginal hysterectomy effects surgical plains and therefore makes the surgical dissection more difficult. this is thought to possibly both add to operative time and increase the rate of complications. the aforementioned studies used the injection of saline as a control for the injection of vasopressin or epinephrine. to date, no study has compared the use of vasopressin versus no injection in a controlled, randomized manner. we do not know if the injection of saline intracervically may actually increase the amount of bleeding over the baseline and therefore the decreased blood loss caused by the injection of vasopressin my actually be overestimated. we propose to compare the effects of injecting vasopressin intracervically preoperatively versus no preoperative medication. we will not only evaluate the amount of operative blood loss, but also compare operative time and complication rates.


Eligibility criteria:
inclusion criteria: * women greater that 18 undergoing vaginal hysterectomy for any indication, with or without concomitant procedures exclusion criteria: * women with a significant medical condition, including severe liver disease, congestive heart failure, documented coronary artery disease, impaired renal function determined by an elevated serum creatinine, asthma with steroid use in the past year, and migraines
universal fixed meal boluses usage in patients with medtronic minimed 780g pumps

Conditions: Type1diabetes

Summary: cross-over study of 20 pediatric patients (age 7-19) randomized to the group receiving universal fixed meal boluses coefficients (300/tdd for breakfast and 400/tdd other meal) or to the group with individualized coefficients for the period of 14 days with consecutive analysis of the results from carelink raport.


Eligibility criteria:
inclusion criteria: * age 7-19 * type 1 diabetes diagnosed at least 1 year ago * insulin in the dose 0,5-1,0 units/day/kg * minimed 780g pump usage at least 1 month. exclusion criteria: * active coeliac disease * chronic disease possible to influence diabetes treatment * acute disease at the moment of recruitment
acceptability of an acupuncture intervention in painful elderly

Conditions: Chronic Pain

Summary: the aim is to investigate the feasibility and efficacy of an acupuncture intervention on persistent musculoskeletar pain in a long-term geriatric hospital care ward population. the main issue is the acceptability of this type of complementary and alternative medicine in older people, although the efficacy on pain is assessed too.

the first 60 patients wanting to participate are enrolled. for the impaired patients, family or legal representing is solicited. the regional ethic committee agreement was granted. the intervention consists in 8 acupuncture sessions. evaluation * acceptability : the proportion of patients who complete the whole treatment ; the acceptability at each acupuncture session is recorded. * pain : dolorous scale . the evaluation is based on pre and post treatment variations. as a high proportion of patients have cognitive impairment, the behavioural pain scale "dolorous" has been chosen after staffs training for all patients, although "extra " auto evaluation is used when possible (evs). evaluation takes place after 5 sessions and after the end of the intervention as well as 2 and 4 weeks after the interventionprofessional carers' satisfaction is recorded.

Eligibility criteria:
inclusion criteria: * age \> 60 years * chronic musculoskeletal pain * follow up 10 weeks * patient or legal representative's agreement to participate and to the informatics treatment of the data exclusion criteria: * acute pain * exclusive neurological pain * coagulation disorders or anticoagulant curative treatment

Keywords: chronic pain > 3 months acupuncture acceptability geriatrics
effectiveness of ultrasound versus fluoroscopy guided s1 injections and radiofrequency

Conditions: Pain, Chronic

Summary: the investigators aim to compare the effect of ultrasound versus floroscopy guided pulsed radiofrequency treatment of the lumbar dorsal root ganglion (drg) of s1 in patients with a chronic lumbosacral radicular pain.


Eligibility criteria:
inclusion criteria: * persistent pain score ≥ 4 on vas, not responding to traditional treatments * radicular pain in lumbar region for 3 months or more, * pattern of radiation suggestive for s1 pathology exclusion criteria: * patient refusal * coagulopathy * uncooperative patients * malignant disorder or currently under treatment for a malignant disorder * pregnancy * leg pain due to localized hip or knee pathology
evaluating the impact of the bridge clinic in patients with opioid use disorder

Conditions: Opioid Use; Opioid-use Disorder

Summary: this study aims to determine whether referral to the bridge clinic reduces overall index hospital length of stay when compared to direct referral to a long-term outpatient addiction provider for patients with active opioid use disorder (oud) being considered for medications-for-addiction treatment (mat).


Eligibility criteria:
inclusion criteria: * inpatients at vuh with active oud being considered for mat. * patient accepting a transitional prescription for buprenorphine-naloxone or im naltrexone whose outpatient plans are not fixed exclusion criteria: * deemed ineligible for referral to outpatient bridge clinic by the addiction consult team (examples include but are not limited to patients with severe, active co-occurring psychiatric disorders requiring a higher level of psychiatric care or patients for whom methadone maintenance is deemed the best choice of mat). * patients previously randomized in this study.
study of bevacizumab followed by bevacizumab consolidation for ovarian cancer

Conditions: Advanced Ovarian Carcinoma; Primary Peritoneal Carcinoma; Ovarian Carcinosarcoma

Summary: the purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and avastin as defined by the proportion of patients able to complete 6 cycles of treatment.

ovarian cancer is the leading cause of death from gynecologic cancer in the united states. the high death rate stems from late presentation and tumor that has spread beyond the ovary at the time of diagnoses. ovarian cancer typically spreads throughout the peritoneal cavity. three randomized clinical trial have recently demonstrated the superiority of intraperitoneal(ip) over intravenous platinum based chemotherapy in optimally debulked advance ovarian cancer. the success of bevacizumab in metastatic colorectal cancer has led to trials evaluating its' efficacy in advanced ovarian cancer. based on the mechanism of action of bevacizumab, there may be benefit of extended therapy with this agent.

Eligibility criteria:
inclusion criteria: * patients with stage ii and iii epithelial ovarian carcinoma, primary peritoneal carcinoma, or ovarian carcinosarcoma. * adequate bone marrow, renal, and hepatic function * patients must be entered no more than twelve weeks postoperatively exclusion criteria: * patients with epithelial ovarian carcinoma of low malignant potential (borderline carcinomas). * stage iv or suboptimally debulked disease following primary cytoreductive surgery * patients who have received prior radiotherapy or chemotherapy.

Keywords: ovarian cancer gynecologic cancer ovarian carcinoma peritoneal carcinoma ip chemotherapy intraperitoneal avastin bevacizumab
investigation on the hesitancy of covid-19 vaccination among liver transplant recipients in china

Conditions: Vaccine Hesitancy

Summary: on wechat platform, through a point-to-point connection, and carry on the questionnaire survey to collect information of liver transplant recipients followed-up by the department of liver surgery, renji hospital shanghai jiao tong university. patients meeting inclusion and exclusion criteria will be selected. conduct statistical analysis to describe the incidence of adverse reactions related to covid-19 vaccine after liver transplantation, and to compare and evaluate the factors leading to covid-19 vaccine hesitancy.

on wechat platform, through a point-to-point connection, and carry on the questionnaire survey to collect information of liver transplant recipients followed-up by the department of liver surgery, renji hospital shanghai jiao tong university. questionnaire items including demographic characteristics, understanding of covid-19, attitude toward covid-19 vaccine. patients meeting inclusion and exclusion criteria will be selected. conduct statistical analysis to describe the incidence of adverse reactions related to covid-19 vaccine after liver transplantation, and to compare and evaluate the factors leading to covid-19 vaccine hesitancy.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 2. recipients after liver transplantation surgery exclusion criteria: 1. incomplete data (missing questionnaire information), such as lack of age, gender, indication for transplantation, time after transplantation and other indicators 2. loss to follow-up 3. covid-19 vaccination before liver transplantation

Keywords: covid-19 vaccine vaccine hesitancy liver transplant recipients china
colometer - a real time quality improvement feedback system for screening colonoscopy

Conditions: Colon Cancer

Summary: our team has created an automated, real-time software based image analysis tool called colometer to improve screening colonoscopy providing real time visual feedback on image quality. there are three components to this study. the first is to validate the bowel assessment preparation using the recorded colonoscopy videos from 50 consented normal risk patients. in the second phase, technological and machine user interface refinements will be identified and completed. finally, the third phase will be a sham controlled prospective study of colometer versus standard care in 100 consented average risk patients undergoing screening colonoscopy as performed by 10 consented endoscopists.


Eligibility criteria:
inclusion criteria: * patients: patients categorized as normal risk who have been referred for screening colonoscopy at the forzani \& macphail colon cancer screening centre in calgary, alberta * endoscopists: gastroenterologists with practices at the forzani \& macphail colon cancer screening centre, calgary, alberta exclusion criteria: * patients: patients who are not categorized as normal risk

Keywords: colonoscopy quality assurance
type of gonadotropin and embryo kinetics of development

Conditions: Infertility

Summary: the study is proposed to determine the effect of three types of gonadotropins that are currently used in protocols of controlled ovarian stimulation in women undergoing in vitro fertilization techniques on the kinetics of embryonic development.


Eligibility criteria:
inclusion criteria: * women \<38 years old * weight \<60 kg * own oocytes * patients have to provide signed informed consent exclusion criteria: * oocyte donors * vitrified oocytes * severe male factor (\<1 million spz/ml) * weight \>60 kg

Keywords: corifollitropin alfa recombinant fsh hp-hmg time-lapse kinetics of development
efficacy and safety of androgel in the treatment of hypogonadal and low testosterone men with type 2 diabetes

Conditions: Type 2 Diabetes; Hypogonadism

Summary: this study is to investigate how well androgel, when tested against placebo gel, helps to control blood sugar levels in males with type 2 diabetes who have low testosterone (the main male hormone) blood levels and are taking oral diabetic medicines alone or in combination with insulin.


Eligibility criteria:
inclusion criteria: 1. able to read and write 2. males 3. between 30-80 years old 4. have type 2 diabetes 5. diagnoses of hypogonadism or low testosterone exclusion criteria: 1. on insulin monotherapy 2. use of testosterone therapy within the last 6 months 3. male breast cancer 4. history of prostate cancer 5. history of clinically significant sleep apnea

Keywords: type 2 diabetes hypogonadism testosterone glycosylated hemoglobin a1c
assessment of service and hearing dogs

Conditions: Impairment; Diabetes; Epilepsy

Summary: for persons with impairments and certain illnesses the use of service dogs may have positive effect. the effects of using these dogs to assist in every day life need to be studied further.the aim of the study was to assess how health care consumption was effected by using certified service dogs and to study the cost-effectiveness of having a certified service dog.

this is an exploratory before and after study with the aim to study how health care consumption was effected by using certified service dogs and to study the cost-effectiveness of having a certified service dog. data was collected before the education of the dog started and the follow-up was made three months after completion of the education. data was collected on health care consumption and outcomes in terms health related quality of life and health outcomes.

Eligibility criteria:
inclusion criteria: * age over 16 years * having a regular companion dog * being in need of a certified service dog (due to impairment, diabetes, epilepsy and deafness) exclusion criteria: * psychiatric illness

Keywords: service dogs alert dogs costs quality of life cost-effectiveness
mowi research pilot

Conditions: Obesity

Summary: the goal of this study is to conduct a program of pilot research aimed at developing and evaluating a technology-assisted wellness intervention for older adults with obesity.

the national epidemic of obesity is also affecting older adults, and is associated with an increased risk of disability, nursing home placement and early mortality. conventional weight loss programs have the potential to reduce body fat, but are difficult to access for older obese adults due to transportation and mobility challenges. the overarching goal of this study is to conduct a program of pilot research aimed at developing and evaluating a technology assisted wellness intervention for older adults with obesity. study timeline: september 2017 to june 2018: goal: conduct a pilot study of improving weight and physical function in older adults with obesity. an mhealth obesity wellness intervention (mowi) will integrate amulet +/- fitbi with a weekly individual dietician-led nutritional session, along with twice weekly physical therapist led group exercise session. participation duration: three times weekly for 3 months

Eligibility criteria:
inclusion criteria: all aims: * age ≥65 years * body mass index (bmi) ≥ 30kg/m\^2 * waist circumference ≥88cm in females or ≥102cm in males aims 2 \& 3: * have wi-fi high speed internet * able to obtain medical clearance from doctor * have less than a 5% weight loss in past 6 months * no advanced co-morbidity * no exercise restrictions * not involved in other research studies that may interfere with participation exclusion criteria: * severe mental or life-threatening illness * dementia * substance use * history of bariatric surgery * suicidal ideation * unable to perform measures * reside in nursing home * no advanced co-morbidity * no exercise restrictions * not involved in other research studies that may interfere with participation aim 4 - had to have completed aims 2 or 3

Keywords: frail elderly telemedicine obesity rural health health promotion weight loss
open label study of r788 in the treatment of persistent/chronic immune thrombocytopenic purpura (itp)

Conditions: Immune Thrombocytopenic Purpura

Summary: the primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic itp


Eligibility criteria:
inclusion criteria: * completed week 24 evaluation of study c935788-047 or study c935788-048 or discontinued early due to lack of response. * able and willing to give written informed consent exclusion criteria: * discontinued participation in study c935788-047 or study c935788-048 for any reason other than lack of response * poorly controlled hypertension during study c935788-047 or study c935788-048 * significant infection, an acute infection such as influenza, or known inflammatory process